#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	2630	16S	1529	1529	99.93	16S.l6.c17.ctg.1	2282	336.1	0	.	n	.	0	C451T	SNP	451	451	C	752	752	T	386	T,C	244,73	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	2630	16S	1529	1529	99.93	16S.l6.c17.ctg.1	2282	336.1	1	SNP	n	C1184T	0	.	.	1184	1184	C	1485	1485	C	391	C	323	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	2630	16S	1529	1529	99.93	16S.l6.c17.ctg.1	2282	336.1	0	HET	.	.	.	C207T,A	.	207	207	C	508	508	C	367	C,T,A	243,59,2	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	4268	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3845	331.5	0	.	n	.	0	T695C	SNP	695	695	T	1148	1148	C	293	C,T	244,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	4268	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3845	331.5	0	.	n	.	0	T1971C	SNP	1971	1971	T	2424	2424	C	377	C	331	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	4268	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3845	331.5	1	SNP	n	C2597T	1	C2597T	SNP	2597	2597	C	3050	3050	T	352	T	289	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	4268	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3845	331.5	1	SNP	n	A2045G	0	.	.	2045	2045	A	2498	2498	A	390	A	331	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
folP.WHO_Y_01480c	folP.WHO_Y_01480c	1	1	27	426	folP	855	855	100.0	folP.l15.c4.ctg.1	2005	63.6	1	SNP	p	R229S	1	.	.	685	687	AGC	1216	1218	AGC	91;91;92	A;G;C	77;77;77	folP.WHO_Y_01480c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	978	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3845	75.8	1	SNP	p	S91F	1	.	.	271	273	TTC	865	867	TTC	92;92;92	T;T;C	79;81;83	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	978	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3845	75.8	1	SNP	p	D95G	1	.	.	283	285	GGC	877	879	GGC	90;91;92	G;G,T;C	83;81,1;82	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	978	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3845	75.8	1	SNP	p	G95N	0	.	.	283	285	GGC	877	879	GGC	90;91;92	G;G,T;C	83;81,1;82	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	27	408	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1874	65.1	1	SNP	p	G45D	0	.	.	133	135	GGC	769	771	GGC	109;110;111	G;G;C	90;89;91	mtrR.WHO_O_01438:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	260	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	1321	58.9	0	.	n	.	0	A197.	DEL	197	197	A	679	679	A	119	A	98	.	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	912	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3312	82.4	1	SNP	p	D86N	0	.	.	256	258	GAC	774	776	GAC	111;110;110	G;A;C	86;85;90	parC.WHO_Y_00247c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	912	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3312	82.4	1	SNP	p	S87R	1	.	.	259	261	CGT	777	779	CGT	110;108;108	C,A;G;T	86,2;83;80	parC.WHO_Y_00247c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	912	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3312	82.4	1	SNP	p	R87W	0	.	.	259	261	CGT	777	779	CGT	110;108;108	C,A;G;T	86,2;83;80	parC.WHO_Y_00247c:1:1:R87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	912	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3312	82.4	1	SNP	p	R87I	0	.	.	259	261	CGT	777	779	CGT	110;108;108	C,A;G;T	86,2;83;80	parC.WHO_Y_00247c:1:1:R87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	912	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3312	82.4	1	SNP	p	S88P	0	.	.	262	264	TCC	780	782	TCC	108;108;107	T;C;C	84;88;86	parC.WHO_Y_00247c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	732	parE	1986	1986	100.0	parE.l15.c4.ctg.1	3092	71.1	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1790	1792	GGC	97;98;98	G;G;C	83;83;82	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.34.001	penA.34.001	1	1	27	706	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2821	74.6	1	SNP	p	A311V	0	.	.	931	933	GCC	1442	1444	GCC	86;86;86	G;C;C	69;67;67	penA.34.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	706	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2821	74.6	1	SNP	p	I312M	1	.	.	934	936	ATG	1445	1447	ATG	87;86;86	A;T;G	71;71;70	penA.34.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	706	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2821	74.6	1	SNP	p	T316P	0	.	.	946	948	ACC	1457	1459	ACC	89;88;88	A;C;C	70;71;68	penA.34.001:1:1:T316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	706	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2821	74.6	1	SNP	p	V316T	1	.	.	946	948	ACC	1457	1459	ACC	89;88;88	A;C;C	70;71;68	penA.34.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	706	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2821	74.6	1	SNP	p	T483S	0	.	.	1447	1449	ACC	1958	1960	ACC	109;109;110	A;C;C	94;93;93	penA.34.001:1:1:T483S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	706	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2821	74.6	1	SNP	p	A501P	0	.	.	1501	1503	GCG	2012	2014	GCG	114;114;114	G;C;G	92;91;94	penA.34.001:1:1:A501P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	706	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2821	74.6	1	SNP	p	A501V	0	.	.	1501	1503	GCG	2012	2014	GCG	114;114;114	G;C;G	92;91;94	penA.34.001:1:1:A501V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	706	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2821	74.6	1	SNP	p	G542S	0	.	.	1624	1626	GGT	2135	2137	GGT	125;125;125	G;G;T	95;95;96	penA.34.001:1:1:G542S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	706	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2821	74.6	1	SNP	p	G545S	1	.	.	1633	1635	AGC	2144	2146	AGC	120;120;120	A;G;C	93;94;91	penA.34.001:1:1:G545S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	706	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2821	74.6	1	SNP	p	P551S	0	.	.	1651	1653	CCG	2162	2164	CCG	119;118;117	C;C;G	87;91;91	penA.34.001:1:1:P551S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	888	ponA	2397	2397	100.0	ponA.l6.c17.ctg.1	3568	74.5	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1869	1871	CCG	75;75;77	C;C;G	58;58;57	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	442	porA	1146	1146	99.91	porA.l15.c4.ctg.1	2186	60.2	0	.	p	.	0	M83fs	FSHIFT	247	247	A	758	758	C	70	C	61	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	96	porB1a	984	297	91.03	porB1a.l15.c17.ctg.1	1252	21.0	0	.	p	.	0	H217N	NONSYN	649	651	CAT	980	982	AAT	11;11;11	A;A;T	9;9;9	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	96	porB1a	984	297	91.03	porB1a.l15.c17.ctg.1	1252	21.0	0	.	p	.	0	D218N	NONSYN	652	654	GAT	983	985	AAT	11;11;11	A;A;T	9;9;9	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	96	porB1a	984	297	91.03	porB1a.l15.c17.ctg.1	1252	21.0	0	.	p	.	0	V226A	NONSYN	676	678	GTA	1007	1009	GCA	11;11;11	G;C;A	9;9;9	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	96	porB1a	984	297	91.03	porB1a.l15.c17.ctg.1	1252	21.0	0	.	p	.	0	.	MULTIPLE	700	702	ACT	1030	1032	GTA	10;10;10	G;T;A	8;8;8	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	96	porB1a	984	297	91.03	porB1a.l15.c17.ctg.1	1252	21.0	0	.	p	.	0	N237fs	FSHIFT	709	709	A	1039	1039	A	10	A	8	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	538	porB1b	1038	1038	99.71	porB1b.l6.c4.ctg.1	2122	75.5	0	.	p	.	0	R40Q	NONSYN	118	120	CGG	613	615	CAG	100;100;100	C;A;G	83;83;83	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	538	porB1b	1038	1038	99.71	porB1b.l6.c4.ctg.1	2122	75.5	0	.	p	.	0	G210R	NONSYN	628	630	GGA	1123	1125	AGA	110;109;109	A,C;G,T;A	97,1;98,1;97	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	538	porB1b	1038	1038	99.71	porB1b.l6.c4.ctg.1	2122	75.5	0	.	p	.	0	S217G	NONSYN	649	651	AGT	1144	1146	GGT	111;111;111	G;G;T	97;91;95	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	538	porB1b	1038	1038	99.71	porB1b.l6.c4.ctg.1	2122	75.5	1	SNP	p	G120K	1	.	.	358	360	AAG	853	855	AAG	113;113;112	A;A;G	96;97;94	porB1b.WHO_Y_02277c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	538	porB1b	1038	1038	99.71	porB1b.l6.c4.ctg.1	2122	75.5	1	SNP	p	A121N	1	.	.	361	363	AAC	856	858	AAC	112;112;113	A;A;C	94;98;97	porB1b.WHO_Y_02277c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	538	porB1b	1038	1038	99.71	porB1b.l6.c4.ctg.1	2122	75.5	1	SNP	p	N121D	0	.	.	361	363	AAC	856	858	AAC	112;112;113	A;A;C	94;98;97	porB1b.WHO_Y_02277c:1:1:N121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	1888	rpoB	4179	4179	99.98	rpoB.l15.c4.ctg.1	5234	107.9	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	284	rpsJ	312	312	100.0	rpsJ.l15.c17.ctg.1	1311	64.3	1	SNP	p	V57M	1	.	.	169	171	ATG	591	593	ATG	123;123;125	A;T;G	102;103;101	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
